160 related articles for article (PubMed ID: 9532585)
1. Multiple sclerosis: IL-2 and sIL-2R levels in cerebrospinal fluid and serum. Review of literature and critical analysis of ELISA pitfalls.
Sivieri S; Ferrarini AM; Gallo P
Mult Scler; 1998 Feb; 4(1):7-11. PubMed ID: 9532585
[TBL] [Abstract][Full Text] [Related]
2. The relationship of interleukin-2 and soluble interleukin-2 receptors to intrathecal immunoglobulin synthesis in patients with multiple sclerosis.
Sharief MK; Hentges R; Thompson EJ
J Neuroimmunol; 1991 Apr; 32(1):43-51. PubMed ID: 2002090
[TBL] [Abstract][Full Text] [Related]
3. Immune activation in multiple sclerosis: study of IL-2, sIL-2R, and gamma-IFN levels in serum and cerebrospinal fluid.
Gallo P; Piccinno MG; Pagni S; Argentiero V; Giometto B; Bozza F; Tavolato B
J Neurol Sci; 1989 Aug; 92(1):9-15. PubMed ID: 2504888
[TBL] [Abstract][Full Text] [Related]
4. Serum and CSF levels of IL-2, sIL-2R, TNF-alpha, and IL-1 beta in chronic progressive multiple sclerosis: expected lack of clinical utility.
Peter JB; Boctor FN; Tourtellotte WW
Neurology; 1991 Jan; 41(1):121-3. PubMed ID: 1985276
[TBL] [Abstract][Full Text] [Related]
5. Elevated soluble interleukin-2 receptor levels in patients with active multiple sclerosis.
Adachi K; Kumamoto T; Araki S
Ann Neurol; 1990 Nov; 28(5):687-91. PubMed ID: 2260855
[TBL] [Abstract][Full Text] [Related]
6. A longitudinal study on IL-2, sIL-2R, IL-4 and IFN-gamma in multiple sclerosis CSF and serum.
Gallo P; Piccinno MG; Tavolato B; Sidén A
J Neurol Sci; 1991 Feb; 101(2):227-32. PubMed ID: 1827837
[TBL] [Abstract][Full Text] [Related]
7. In vivo relationship of interleukin-2 and soluble IL-2 receptor to blood-brain barrier impairment in patients with active multiple sclerosis.
Sharief MK; Hentges R; Ciardi M; Thompson EJ
J Neurol; 1993 Jan; 240(1):46-50. PubMed ID: 8423463
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2, soluble interleukin-2-receptor, neopterin, L-tryptophan and beta 2-microglobulin levels in CSF and serum of patients with relapsing-remitting or chronic-progressive multiple sclerosis.
Ott M; Demisch L; Engelhardt W; Fischer PA
J Neurol; 1993 Dec; 241(2):108-14. PubMed ID: 8138825
[TBL] [Abstract][Full Text] [Related]
9. Prospective serial analysis of interleukin-2 and soluble interleukin-2 receptor in relapsing-remitting multiple sclerosis.
Freedman MS; Muth KL; Trotter JL; Yoshizawa CN; Antel JP
Neurology; 1992 Aug; 42(8):1596-601. PubMed ID: 1641157
[TBL] [Abstract][Full Text] [Related]
10. [Changes of serum interleukin 2 and soluble interleukin 2 receptor and their clinical significance in multiple myeloma].
Wang Z; Li D; Yang J
Zhonghua Zhong Liu Za Zhi; 1996 Nov; 18(6):439-41. PubMed ID: 9387297
[TBL] [Abstract][Full Text] [Related]
11. Correlations between IL-4, IL-12 levels and CCL2, CCL5 levels in serum and cerebrospinal fluid of multiple sclerosis patients.
Bartosik-Psujek H; Stelmasiak Z
J Neural Transm (Vienna); 2005 Jun; 112(6):797-803. PubMed ID: 15480850
[TBL] [Abstract][Full Text] [Related]
12. [Clinical course and changes of soluble interleukin-2 receptor and soluble forms of intercellular adhesion molecule-1 (ICAM-1) in serum of multiple sclerosis patients].
Bilińska M; Frydecka I; Podemski R
Neurol Neurochir Pol; 2001; 35(1):47-56. PubMed ID: 11464716
[TBL] [Abstract][Full Text] [Related]
13. Correlation of interleukin-2 and soluble interleukin-2 receptor with clinical activity of multiple sclerosis.
Sharief MK; Thompson EJ
J Neurol Neurosurg Psychiatry; 1993 Feb; 56(2):169-74. PubMed ID: 8437006
[TBL] [Abstract][Full Text] [Related]
14. Serum interleukin 2 and soluble interleukin 2 receptor in chronic active hepatitis C: effect of interferon therapy.
Simsek H; Kadayifci A
J Int Med Res; 1996; 24(3):239-45. PubMed ID: 8725984
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid levels of myelin basic protein-like material and soluble interleukin-2 receptor in multiple sclerosis.
Fesenmeier JT; Whitaker JN; Herman PK; Walker DP
J Neuroimmunol; 1991 Oct; 34(1):77-80. PubMed ID: 1716642
[TBL] [Abstract][Full Text] [Related]
16. CSF and serum levels of soluble interleukin-6 receptors (sIL-6R and sgp130), but not of interleukin-6 are altered in multiple sclerosis.
Padberg F; Feneberg W; Schmidt S; Schwarz MJ; Körschenhausen D; Greenberg BD; Nolde T; Müller N; Trapmann H; König N; Möller HJ; Hampel H
J Neuroimmunol; 1999 Oct; 99(2):218-23. PubMed ID: 10505978
[TBL] [Abstract][Full Text] [Related]
17. Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission.
Shaw CE; Dunbar PR; Macaulay HA; Neale TJ
J Neurol; 1995 Jan; 242(2):53-8. PubMed ID: 7707089
[TBL] [Abstract][Full Text] [Related]
18. Elevated interleukin 2 levels in serum and cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis.
Tomioka R; Hamaguchi K; Ohno R; Hosokawa T; Kaneko A; Tsuji T; Kurihara K
Ann N Y Acad Sci; 1992 Apr; 650():347-50. PubMed ID: 1605493
[No Abstract] [Full Text] [Related]
19. Soluble interleukin-2 receptor and soluble CD8 molecules in cerebrospinal fluid and serum of patients with multiple sclerosis.
Carrieri PB; Soscia E; Iacovitti B; Pellicano M; D'Antonio A; Provitera V; Perrella O
Eur Cytokine Netw; 1992; 3(5):495-8. PubMed ID: 1477299
[TBL] [Abstract][Full Text] [Related]
20. Determination of interleukin-2 (IL-2) and soluble IL-2 receptors (S-IL-2R) in serum and cerebrospinal fluid does not discriminate purulent and aseptic meningitis.
Larsen CS; Bjerager M
Scand J Infect Dis; 1990; 22(3):327-31. PubMed ID: 2371547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
